Tangoe

Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering and delivering the next generation of precision oncology medicines. The company leverages its proprietary functional genomics platform, based on the principle of synthetic lethality, to identify novel targets that are specifically lethal to cancer cells while sparing healthy ones. Their lead programs, TNG908 and TNG462, are brain-penetrant, MTA-cooperative PRMT5 inhibitors designed to treat cancers with MTAP deletions, which occur in approximately 10% of all human tumors. Additionally, Tango is developing TNG260, a CoREST inhibitor aimed at reversing immune evasion in STK11-mutant cancers. The company maintains a strategic collaboration with Gilead Sciences to expand its pipeline of target discovery and drug development. Tango's approach focuses on addressing high unmet needs in oncology by targeting specific genetic alterations in difficult-to-treat solid tumors.